First test: how a new heart drug behaves in damaged livers
NCT ID NCT05481411
Summary
This early-stage study aimed to understand how a single dose of the experimental drug olpasiran is processed by the body in people with different levels of liver damage. It compared 25 participants with mild, moderate, or severe liver impairment to participants with normal liver function. The main goal was to check if the drug's behavior and safety profile changed based on liver health, which is a standard step before testing in larger patient groups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Inland Empire Clinical Trials, LLC
Rialto, California, 92377, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
-
The Texas Liver Institute, Inc.
San Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.